×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Skip to main content
Tags: BUSINESS | COS | DRG | EXE | GEN | GOV | HEA

White House Confident J&J Will Meet Vaccine Shipment Targets

White House Confident J&J Will Meet Vaccine Shipment Targets
(Dreamstime)

Thursday, 01 April 2021 03:34 PM EDT

President Joe Biden’s administration is “assured” that Johnson & Johnson will meet its U.S. vaccine delivery targets despite a setback at a Baltimore site, White House Press Secretary Jen Psaki said.

Psaki spoke Thursday at the White House after J&J and one of its subcontractors, Emergent BioSolutions Inc., acknowledged that a batch of drug substance had been spoiled. She said the U.S. doesn’t expect J&J to miss any delivery targets, and alluded to having some room with a larger supply of Pfizer Inc. and Moderna Inc. The U.S. has said it will have enough vaccine doses for all American adults in May from those companies.

“We have been assured that they expect to meet those deadlines,” Psaki said, when asked about J&J. “We are looking forward to that. Obviously, these are doses that the U.S. government has purchased but we also have plenty of doses from Pfizer and Moderna, regardless.”

The disruption affected a batch of drug substance at a Baltimore plant that isn’t yet authorized to produce doses, and has not provided any to the U.S. so far. It’s not expected to affect Biden’s May target, several people familiar with the matter have said.

Psaki said the Department of Health and Human Services informed the White House late last week, but didn’t say when HHS learned of the problem at the facility.

Flawed Batch

In a statement Thursday, Emergent said it has set up rigorous quality checks that caught the flawed batch. “Through these checks a single batch of drug substance was identified that did not meet specifications and our rigorous quality standards. We isolated this batch and it will be disposed of properly,” it said.

The company called the issue disappointing yet said it “does occasionally happen during vaccine manufacturing, which is a complex and multi-step biological process.”

Emergent says it remains “confident” in its ability to meet Food and Drug Administration requirements and receive authorization.

J&J said it remains on pace to deliver the U.S. order by the end of June. The administration has said it wants all of the supply or nearly all of it by the end of May; J&J hasn’t committed to meeting that timeline.

© Copyright 2022 Bloomberg News. All rights reserved.


US
BUSINESS, COS, DRG, EXE, GEN, GOV, HEA, INDUSTRIES, NORTHAM, TOP, US, WORLD, WWTOP, WWTOPAM
361
2021-34-01
Thursday, 01 April 2021 03:34 PM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved
Download the NewsmaxTV App
NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved